Reddit Posts
FULL Nasdaq Article by Ari Zoldan: How Three Companies Are Taking Aim at Alleged Naked Short Sellers - 28 Nov 2023 - (immortalized in photos + links)
NRXP FDA provided Written Responses on January 10 th. As previously announced in October 2022 , an updated NRX-101 module 3 was submitted to add the intended commercial manufacturer to the IND. With FDA's written response, it appears that NRx Pharmaceuticals has reached alignment with the FDA
BREZ has the best risk/reward for SPACs since CCIV in 2021 at $12, low float with huge call OI for May + gamma squeeze potential
It’s criminal for Fauci to delay approval of Zyesami from $NRXP and $RLFTF. Now Ted Cruz is all over it to make sure it happens…link below. This needs to be all over Fox News, joe Rogan, etc ASAP
Senator Ted Cruz pressing Fauci for why RLFTF (relief) and NRXP’s Zyesami hasn’t gotten eua yet and is saving lives from covid!!!!. Guys you need to see this. This needs fo be blasted ALL over the news. This is criminal what the FDA does. PLEASE READ the link below. CONGRESS is all over this!!!!
NRXP, 673K shares bought by someone, Zyesmi works for COVID patients
NRXP Short Volume 55%, Is it setting up for a squeeze?
NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge
NRx Pharmaceuticals (NRXP) CEO to Provide Business Update on January 10th
Relief Therapeutics (RLF.SW, RLFTF) Is flying again today, NRXP will follow too.
Proud holding Relief Therapeutics (RLF.SW, RLFTF) & NRXP! https://miamicourant.com/stories/617928153-op-ed-the-emergency-use-law-should-be-used-for-emergencies-like-now
Relief Therapeutics (RLF.SW, RLFTF) flying today 46% and more to come🤞, NRXP just released a PR for a new EUA submission. With this one approved both of them will have a huge run!
NRXP Stock Rumbles On Request For Therapy Designation.
NRXP NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil)
NRXP 0 shares available, has filled gap back down after its covid variant vaccine PR. Said they will be testing on new variant
$NRXP Zyesemi and BriLife is the Covid19 game changer. Don’t miss on this one (like I almost missed LGVN).
Play for tomorrow is BMTX and NRXP 🚀🚀🎉🎉🎰🎰 Don’t miss this one out!!
NRXP- held up nicely today as still 23% up from Friday close
NRXP Covid Vaccine don't sleep on it, I see it squeezing back to high 9s 😉💥
CONFUSED! NRXP Study looks towards EUA but price still falling? Any Medical People know why?
NRXP Stock: Aviptadil Effective In Increasing COVID Recovery Odds & Surv...
$NRXP is the play, 23M float, 4.5% short of float (Finviz).
NRXP NEWS Out! Low float, FDA Pending Up Pre-Market!
NRXP 💥 💥 Great PR today, this can go easily to 100$ 🚀 🚀
NRXP - the covid vaccine that may be able to evolve to combat different variants
NRXP anyone, 50% today was even at 80% intraday? Vaccine for Covid plus a potential therapeutic Zyesami/aviptadil (currently in NIH trial h2h with Remdesivir). Good news today from their vaccine trials and seems that this beauty can run fast 💥 💥
NRXP 52W High was 76$ it's currently sitting at 7$, this is a no brainer with Covid Variant all over the news 😉💥
NRXP Stock: Vaccine May Be Capable Of Evolving To Counter Variants. NRX ...
NRXP looks very good, new COVID vacine trail phase 2
NRXP Delta Covid News excellent entry on pullback 💥 Should see 10+
New guy here. Tell me about NRXP. Low float, high short volume and FDA pending drug. Is this a buy? Thanks!
What do an US General, a Professor of Medicine, Head of Mossad, Erectile Dysfunction, and Short Hedge Funds have in common? - The answer may surprise you. (Story of NRX Pharmaceuticals, NRXP)
What do an US General, a Professor of Medicine, Head of Mossad, Erectile Dysfunction, and Short Hedge Funds have in common? - The answer may surprise you. (Story of NRX Pharmaceuticals, NRXP)
What do an US General, a Professor of Medicine, Head of Mossad, Erectile Dysfunction, and Short Hedge Funds have in common? - Story of NRXP
#premarket #watchlist 10/14 $GRVI - Grove, Inc. Launches Amazon Aggregation Division , $NRXP - NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale Development of ZYESAMI™ , $TSRI -Reports Record Revenue for the First Quar... Any trading ideas? Welcome in comments!
NRXP has a bit of a double bottom happening today Potential for a 10% spike by close
NRXP Full DD: Big mover (up 61% yesterday) and ridiculously cheap stock
Bio stocks - how to not get burnt ?
$NRXP cost to borrow 194%+ - potential FDA approval and covid treatment in the pipe… rack em up
Thoughts on NRXP? Saw their borrow rate at 130% only 10k shares left to borrow?
BYSI and NRXP still my main biotech plays. BYSI lung cancer drug / NRXP COVID therapeutic
Mentions
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year -HUBC: $920k cash vs $129.5m in current liabilities
For a dead cat bounce or short term play, you guys can consider LNKS, its making moves in the overnight market. Longer term u can consider NRXP
NRXP still moving strong
NRXP is slowly slowly heading upwards. Potential re rating soon!!
NRXP CGTX!!! Lets go FEMY BOIS
is anyone in NRXP? [https://www.tradingview.com/news/reuters.com,2026:newsml\_L8N40C1JP:0-nrx-pharmaceuticals-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/](https://www.tradingview.com/news/reuters.com,2026:newsml_L8N40C1JP:0-nrx-pharmaceuticals-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/)
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
Yes! I'm invested in a few other cancer stocks that could go high based on current share price - MAIA, AUTL, CHRS. But IOVA is a strong contender. Outside of that I'd bet DVLT, NRXP and FEMY (heavy on this choice because they have so much going for them).
NRXP news today is legit. Its a speculative 2-4 year play.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
Y'all are still shilling this one eh? - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
Waiting for MIST, NRXP, and AUID for news. One of these days.
NRXP watch for approval timeline
I bought $NRXP at the peak thinking the Jan 26 deadline meant something bullish would happen. Turns out it's just SEC compliance theater. At least I mapped the damage here: [$NRXP](https://aimytrade.io/s/NRXP?utm_source=reddit&utm_medium=comment&utm_campaign=RobinHoodPennyStocks&utm_term=NRXP&utm_content=variant_1771448538690_m30cf6)
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
NRXP has to pull out of the hole it got dropped in. It was holding solid over $2.
NRXP and CABA looking good rn!!
How t f are you making money with NRXP? it's been a bloodbath from the beginning..I seriously have the CEO, but can't sell yet, too far down
I've followed NRXP for a while. No way you 2.5 call on that is in the money like youre showing. Fake.
*SCAM ALERT* The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert • NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution • BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution • NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution • OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. • MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
Here are some examples of commonly posted/pumped stocks will horrendous balance sheets. I anticipate every single one of these companies will massively dilute shareholders within the next 6-12 months in an attempt to stay afloat. I doubt it'll work. NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
LMAO more dilutive debt. Ontop of: The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert • NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution • BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution • NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution • OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. • MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
NRXP is bottoming on 36x their 90 day average volume on news that they’re trying to accelerate FDA approval 👀
Hopefully I can nab some at open NRXP - submitted 70,000 real world patient reviews datset with their already submitted fda application
NRXP! Mark my words it will be a 10 bagger in 2 years time
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
I'm not sure what to tell you at this point lol. I will just plug my usual copy+paste. Be careful with holding any of these guys for any meaningful amount of time The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
NRXP. I've mentioned it multiple times in other subs. Preservative free ketamine with positive results. Expected FDA approval in the summer. They've got another promising drug in the pipeline. Huge 10x potential.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively I floated by goodwill.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. -ASBP: $1.95m in cash and $13.86m in debt/payables due this year -SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. **Was $41m, but they diluted to pay off debt
I appreciate the general advice on checking balance sheets. That's always good practice. I did notice, though, that you updated your post after someone pointed out NRXP recently cleared their debt, yet they're still included on this list. I've also seen similar posts from you in a few other threads. Beyond the debt situation, NRXP just announced a joint offering with neurocare Group AG for neuroplastic therapy targeting depression. That was just yesterday. They're also advancing NRX-101 through the FDA pipeline. This doesn't exactly fit the profile of a company waiting for a pump to dump shares before bankruptcy. Not making accusations, but when the facts have changed and the narrative hasn't, it's fair to ask: is there a short position here that's getting uncomfortable with the momentum?
REMINDER! The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
There are so many every day that I've genuinely gotten bored of reposting lol The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
NRXP and ASBP both waiting on FDA feedback that is a few days overdue.
NRXP is also late on FDA news.
Didn't NRXP recently pay off their debt?
Good post. As a fellow scam hater, I feel this is an appropriate place to share my Big List of Stupid Balance Sheets: The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.
Thanks for sharing this detailed analysis! The potential for a short squeeze with NRXP is intriguing, especially given the upcoming FDA decision and the comparison to OMER's past performance. The fact that the company is actively expanding clinics and eliminating debt adds to the positive outlook. With such a clearly defined timeline and
All of these analysts, with the exception of one (I think), have abysmal success rates. Every last one of them doesn't have a rate of return that comes ANYWHERE near what they are projecting the gain to be on NRXP. That's to say that their average return would be materially impacted by this one stock, but all of their average returns are awful. Which lends to the fact that HC Wainwright always issues absurd price targets and the stocks never see them, as reflected in the analysts average rate of return.
Love this question. First, that PT is just one analysts PT. The average is $36.75 but that's neither here nor there. Now to the nuts and bolts of that absolutely ABSURD PT. The analysts that have PTs issued on the stock ALL have a conflict of interest. The representation comes from HC Wainwright (notorious for issuing PTs that could pass as being issued by someone smoking crack), BTIG (serves as a financial advisor and acquisition advisor), D Boral Capital (performed shelf offerings for NRXP), and Ascendiant Capital (assists in capital raises/financing solutions). It quite literally best serves them to effectively sell the stock as this pipedream that it very much is not so that they can achieve optimal outcomes for them via the other services they provide NRXP. Also, NRXP makes sure to publish each of the "research reports" on their website so you can easily access the reports that "support" these PTs that aren't rooted in reality in the slightest. It's not a common practice amongst companies that are confident in their outcomes. Also, it's important to note these are 12 month price targets and the price target has been at the same place since like 2022 and just gets reiterated 100 times over. So instead of 12 months, you can really call it a 48 month target. Also, by my estimation, I think you will be lucky to see the stock hit even the low end of the range ($25) for more than 30 minutes when it does jump upon approval should it happen. Shorts will cover and spike it artificially but then I think it comes back to $7.50 in the end.
NXXT shills out in full force again today. Don't forget.. The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.
The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.
The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.
The Big List of Stupid Balance Sheets - 2026 - Update 1 - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.
IMPENDING BANKTUPTCY ALERT: MNTS $670k in cash with a whopping $17.3 million in debt/payables due this year. MNTS joins NXXT, BURU, and NRXP on: The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution Please comment with other Stupid Balance Sheets
I thought about NRXP but I’m just gonna hold off. I made a lot from sept and oct. Then lost about half of that in mid dec
Yeah, nothing is jumping out for me today. Premarket averaged down a bit on OTLK and opened small position on NRXP (300 shares at $2.73) but nothing else, and may not do anything else.
Had to read this comment three times. Thought you said it is Outlook Therapeutics birthday... today is going to be a long one. Unless NRXP get their verdict!
NRXP. Less than 5 years. Preservative free ketamine with expected FDA approval in July 2026.
i hope at least once u bought NRXP yesterday lol up pretty nicely today
NRXP is a good buy right now it refuses to go under 2 dollars
NRXP. Preservative free ketamine with expected FDA approval in summer 2026. This thing has legit 10x potential. SONY. Long history of outpacing the S&P. Gigantic company. 3rd choice is kind of up in the air. Personally I'd say go with some kind of precious metals etf (gold is my go to).
Just gonna continue buying SONY and NRXP.
BCRX seams good. Take a look at NRXP
Have faith in the NRXP, especially after today's news!
https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-and-hope-therapeutics-to-present-at-awfvzw0gzd6n.html
Bought some NRXP ready for tomorrow
NRXP is making moves again. Presentation announced today to take place tomorrow but they have already uploaded the slides on their site: [https://www.nrxpharma.com/wp-content/uploads/2025/10/NRx-Corporate-Presentation.pdf](https://www.nrxpharma.com/wp-content/uploads/2025/10/NRx-Corporate-Presentation.pdf) . They expect 2 PDUFAs in 2025 (but in my view we could end up waiting until 26q1) and their work with HOPE Therapeutics clinics is expanding. 8-K filing from late 2024/early 2025 (I forget exactly when) states expected PDUFA date for one of their drugs to be 30th December. The drug deals with the effects of suicidal depression and the presentation claims this is an addressable market of 2 billion USD (compared to a market cap of 67m USD). Disclaimer: I have been in this since August. I have taken profits and bought dips in that time. This is the last push before the expected PDUFA date of 30 Dec 25. Not financial advice.
My personal plays this month are HUBC and NRXP
NRXP had some big names buy in this month. lots of big catalysts late December-mid 2026. [https://fintelco.ca/so/us/nrxp](https://fintelco.ca/so/us/nrxp)
NOT A DAY TRADE, NRXP is a possible rocket 2 drugs approaching possible fda approval and opening 6 more cash generating clinics under there subsidiary hope therapeutics. At $2.39, PT 35-45 from multiple sources. DD is my second last post(click my profile and go to posts) not updated for earnings but they weren’t bad you can look them up.
Just a heads up NOT A PUMP AND DUMP/NOT A DAY TRADE NRXP Upcoming PDUFA’s $NRXP (Biotechnology) - Price: 2.39USD - Market Cap: 62.76M - Shares Float: 21.02M - Q3 2025 earnings call on November 17, 2025 - Q2 2025 ended with $5.5M; bolstered by $6.5M direct offering. Sufficient runway into 2026 without dilution. NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders. Particularly, suicidal bipolar depression, chronic pain, and PTSD. Their pipeline leverages an NMDA platform and includes two key candidates: NRX-100 (preservative-free intravenous ketamine) and NRX-101 (a combination of D-cycloserine and lurasidone). NRX-100 Key Details: - NDA filing completed in Q2 2025; complemented by an Abbreviated New Drug Application (ANDA) for broader ketamine shortage response. - NRXP has non-binding licensing terms with a major pharma partner, potentially yielding $300M in milestones and double-digit royalties upon approval, targeting a >$3B U.S. suicidal depression market. - Fast Track Designation granted. - $4.3 million filing fee waived by FDA. - Supported by data from four clinical trials (including NIH-sponsored studies) and French health authority data. - Targets a $3B+ U.S. market; partnered with Nephron Pharmaceuticals for U.S.-based manufacturing. - Stability data supports 3 years of room-temperature shelf life. NRX-101 Key Details: - NDA filing planned/underway for Accelerated Approval. - NRX-101 targets unmet needs in suicidal bipolar depression treatment, with potential partnerships (e.g., Alvogen for marketing) and a projected market impact alongside NRX-100. - Breakthrough Therapy Designation. - Based on Phase 2b/3 and STABIL-B trial data. - Three manufacturing lots completed with >2 years of room-temperature stability. - Aims to address unmet needs in bipolar depression treatment. (AI Assisted)
NRXP was featured on Bloomberg TV last night on the show New To The Street. Could give the company some decent exposure
Also over the weekend do some DD on NRXP. I do have a few hundred into it, it’s not a day trade play but the upside(if everything goes well in PDUFA) is 10x+. Currently at 2.15, price projections are between 10-45
NRXP doing its usual 5% daily climb
Also i want everyone to at least check out NRXP it hasn’t gone under 2 dollars in a year pretty much , price targets range from 20-45 dollars across various sources , Matthew Rockefeller recently joined the board of directors as well , the ceo Dr Javitt seems to be close with the government as well, he is a former PITAC under Bush administration and he also served under the Department of Defense after 9/11